Skyrizi (Risankizumab-Rzaa) Patent Expiration, LOE Window & CMS Spending

Skyrizi (Risankizumab-Rzaa) by AbbVie: Biologic BLA (Purple Book Regime), 0 AB generics, $479.9M 2024 CMS Part D & Medicaid spend, and 13 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayB761105 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$479.9M
2024 Medicare Part D Spend$315.6M
2024 Medicaid Spend$164.3M
Reported Wholesale Price Change (CA SB 17)13 WAC filings (max 24.6% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.